Search: onr:"swepub:oai:DiVA.org:uu-358199" >
Autologous Transpla...
-
Casulo, CarlaUniv Rochester, Wilmot Canc Inst, New York, NY USA
(author)
Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure : A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis
- Article/chapterEnglish2018
Publisher, publication year, extent ...
-
Elsevier BV,2018
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-358199
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-358199URI
-
https://doi.org/10.1016/j.bbmt.2017.12.771DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:138548517URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS). We analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National LymphoCare Study (NLCS) to determine whether autologous hematopoietic cell transplant (autoHCT) can improve outcomes in this high-risk FL subgroup. ETF was defined as failure to achieve at least partial response after frontline chemoimmunotherapy or lymphoma progression within 2 years of frontline chemoimmunotherapy. We identified 2 groups: the non-autoHCT cohort (patients from the NLCS with ETF not undergoing autoHCT) and the autoHCT cohort (CIBMTR patients with ETF undergoing autoHCT). All patients received rituximab-based chemotherapy as frontline treatment; 174 non-autoHCT patients and 175 autoHCT patients were identified and analyzed. There was no difference in 5-year OS between the 2 groups (60% versus 67%, respectively; P = .16). A planned subgroup analysis showed that patients with ETF receiving autoHCT soon after treatment failure (≤1 year of ETF; n = 123) had higher 5-year OS than those without autoHCT (73% versus 60%, P = .05). On multivariate analysis, early use of autoHCT was associated with significantly reduced mortality (hazard ratio, .63; 95% confidence interval, .42 to .94; P = .02). Patients with FL experiencing ETF after frontline chemoimmunotherapy lack optimal therapy. We demonstrate improved OS when receiving autoHCT within 1 year of treatment failure. Results from this unique collaboration between the NLCS and CIBMTR support consideration of early consolidation with autoHCT in select FL patients experiencing ETF.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Friedberg, Jonathan W.Univ Rochester, Wilmot Canc Inst, New York, NY USA
(author)
-
Ahn, Kwang W.Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA
(author)
-
Flowers, ChristopherEmory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA 30322 USA
(author)
-
DiGilio, AlyssaMed Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA
(author)
-
Smith, Sonali M.Univ Chicago, Sect Hematol Oncol, Chicago, IL 60637 USA
(author)
-
Ahmed, SairahUniv MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX USA
(author)
-
Inwards, DavidMayo Clin, Div Hematol, Rochester, MN USA
(author)
-
Aljurf, MahmoudKing Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riydah, Saudi Arabia
(author)
-
Chen, Andy, IOregon Hlth & Sci Univ, Blood & Marrow Transplant Program, Portland, OR 97201 USA
(author)
-
Choe, HannahWeill Cornell Med Coll, Blood & Marrow Transplant Program, New York, NY USA
(author)
-
Cohen, JonathonEmory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA 30322 USA
(author)
-
Copelan, EdwardCarolinas HealthCare Syst, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA
(author)
-
Farooq, UmarUniv Iowa, Dept Med, Iowa City, IA 52242 USA
(author)
-
Fenske, Timothy S.Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA
(author)
-
Freytes, CesarTexas Transplant Inst, Blood & Marrow Transplant Program, San Antonio, TX USA
(author)
-
Gaballa, SamehThomas Jefferson Univ Hosp, Blood & Marrow Transplant Program, Philadelphia, PA 19107 USA
(author)
-
Ganguly, SiddharthaUniv Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Kansas City, KS 66103 USA
(author)
-
Jethava, YogeshUniv Arkansas Med Sci, Blood & Marrow Transplant Program, Little Rock, AR 72205 USA
(author)
-
Kamble, Rammurti T.Baylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX 77030 USA
(author)
-
Kenkre, Vaishalee P.Univ Wisconsin, Div Hematol & Oncol, Madison, WI USA
(author)
-
Lazarus, HillardUniv Hosp Cleveland, Seidman Canc Ctr, Med Ctr, Cleveland, OH 44106 USA
(author)
-
Lazaryan, AleksandrUniv Minnesota, Blood & Marrow Transplant Program, Minneapolis, MN USA
(author)
-
Olsson, RichardKarolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden(Swepub:uu)riols677
(author)
-
Rezvani, Andrew R.Stanford Hlth Care, Blood & Marrow Transplant Program, Stanford, CA USA
(author)
-
Rizzieri, DavidDuke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA
(author)
-
Seo, SachikoEast Hosp, Natl Canc Res Ctr, Chiba, Japan
(author)
-
Shah, Gunjan L.Mem Sloan Kettering Canc Ctr, Blood & Marrow Transplant Program, 1275 York Ave, New York, NY 10021 USA
(author)
-
Shah, NinaUniv MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX USA
(author)
-
Solh, MelhamNorthside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA
(author)
-
Sureda, AnnaInst Catala Oncol Hosp, Hematol Dept, Barcelona, Spain
(author)
-
William, BasemOhio State Med Ctr, James Canc Ctr, Columbus, OH USA
(author)
-
Cumpston, AaronWest Virginia Univ Hosp, Blood & Marrow Transplant Program, Morgantown, WV USA
(author)
-
Zelenetz, Andrew D.Mem Sloan Kettering Canc Ctr, Blood & Marrow Transplant Program, 1275 York Ave, New York, NY 10021 USA
(author)
-
Link, Brian K.Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA
(author)
-
Hamadani, MehdiMed Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA
(author)
-
Univ Rochester, Wilmot Canc Inst, New York, NY USAMed Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA
(creator_code:org_t)
Related titles
-
In:Biology of blood and marrow transplantation: Elsevier BV24:6, s. 1163-11711083-87911523-6536
Internet link
Find in a library
To the university's database
- By the author/editor
-
Casulo, Carla
-
Friedberg, Jonat ...
-
Ahn, Kwang W.
-
Flowers, Christo ...
-
DiGilio, Alyssa
-
Smith, Sonali M.
-
show more...
-
Ahmed, Sairah
-
Inwards, David
-
Aljurf, Mahmoud
-
Chen, Andy, I
-
Choe, Hannah
-
Cohen, Jonathon
-
Copelan, Edward
-
Farooq, Umar
-
Fenske, Timothy ...
-
Freytes, Cesar
-
Gaballa, Sameh
-
Ganguly, Siddhar ...
-
Jethava, Yogesh
-
Kamble, Rammurti ...
-
Kenkre, Vaishale ...
-
Lazarus, Hillard
-
Lazaryan, Aleksa ...
-
Olsson, Richard
-
Rezvani, Andrew ...
-
Rizzieri, David
-
Seo, Sachiko
-
Shah, Gunjan L.
-
Shah, Nina
-
Solh, Melham
-
Sureda, Anna
-
William, Basem
-
Cumpston, Aaron
-
Zelenetz, Andrew ...
-
Link, Brian K.
-
Hamadani, Mehdi
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Hematology
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Biology of blood ...
- By the university
-
Uppsala University
-
Karolinska Institutet